Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The glutamate uptake system, primarily mediated by the excitatory amino acid transporter (EAAT) family, is the principal mechanism for removing the excitatory neurotransmitter glutamate from the extracellular space in the central nervous system (Danbolt, 2001, Progress in Neurobiology). This system is crucial for terminating synaptic transmission and maintaining extracellular glutamate at sub-micromolar levels to prevent excitotoxicity, a process where excessive glutamate leads to neuronal overstimulation and death (Jensen et al., 2015, Neurochemistry International). There are five human EAAT subtypes (EAAT1-5), with EAAT2 (GLT-1) being responsible for the majority of glutamate clearance in the forebrain (UniProt P43004). Dysfunction or downregulation of these transporters is a hallmark of several neurodegenerative and psychiatric conditions, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and epilepsy (Kong et al., 2014, Journal of Biological Chemistry). Pharmacological modulation of the glutamate uptake system, particularly through the upregulation of EAAT2 expression by drugs like riluzole or experimental compounds like LDN-212320, represents a significant therapeutic strategy for neuroprotection (NIH/NCBI Gene ID 6506). However, achieving subtype specificity and effective blood-brain barrier penetration remains a challenge for drug development in this area.
Modulation of glutamate uptake through transcriptional upregulation of transporter proteins (e.g., EAAT2) or direct allosteric activation of transport kinetics (Danbolt, 2001; Kong et al., 2014).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Excitatory amino acid transporter (EAAT) (EAAT).